Survival of European patients with central nervous system tumors

International Journal of Cancer - Tập 131 Số 1 - Trang 173-185 - 2012
Milena Sant1, Pamela Minicozzi1, Susanna Lagorio2, Anne‐Marie Bouvier3, Rafael Marcos‐Gragera4, Silvia Francisci2
1Analytical Epidemiology Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan, Italy
2National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanità, Viale Regina Elena, 299 Rome, Italy
3Cancer Registry of Norway, Department of Clinical and Registry-based Research, Institute of Population-based Cancer Research, Fridj of Nansens vei 19, Majorstuen, Oslo, Norway
4Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health and Catalan Institute of Oncology, Girona, Spain

Tóm tắt

AbstractWe present estimates of population‐based 5‐year relative survival for adult Europeans diagnosed with central nervous system tumors, by morphology (14 categories based on cell lineage and malignancy grade), sex, age at diagnosis and region (UK and Ireland, Northern, Central, Eastern and Southern Europe) for the most recent period with available data (2000–2002). Sources were 39 EUROCARE cancer registries with continuous data from 1996 to 2002. Survival time trends (1988 to 2002) were estimated from 24 cancer registries with continuous data from 1988. Overall 5‐year relative survival was 85.0% for benign, 19.9% for malignant tumors. Benign tumor survival ranged from 90.6% (Northern Europe) to 77.4% (UK and Ireland); for malignant tumors the range was 25.1% (Northern Europe) to 15.6% (UK and Ireland). Survival decreased with age at diagnosis and was slightly better for women (malignant tumors only). For glial tumors, survival varied from 83.5% (ependymoma and choroid plexus) to 2.7% (glioblastoma); and for non‐glioma tumors from 96.5% (neurinoma) to 44.9% (primitive neuroectoderm tumor/medulloblastoma). Survival differences between regions narrowed after adjustment for morphology and age, and were mainly attributable to differences in morphology mix; however UK and Ireland and Eastern Europe patients still had 40% and 30% higher excess risk of death, respectively, than Northern Europe patients (reference). Survival for benign tumors increased from 69.3% (1988–1990) to 77.1% (2000–2002); but survival for malignant tumors did not improve indicating no useful advances in treatment over the 14‐year study period, notwithstanding major improvement in the diagnosis and treatment of other solid cancers.

Từ khóa


Tài liệu tham khảo

10.1093/neuonc/1.3.205

10.3171/jns.2003.99.3.0458

10.1007/s11060-010-0240-7

10.1002/ijc.21255

10.1007/s11060-009-9938-9

10.1016/S0959-8049(98)00336-0

10.3171/foc.2006.20.4.E1

10.1016/j.critrevonc.2007.03.004

10.1016/j.critrevonc.2008.02.005

10.1016/j.critrevonc.2008.01.010

10.1016/j.ejca.2008.11.003

10.1016/j.ejca.2003.10.013

Fritz A, 2000, International classification of diseases for oncology (ICD‐O), 218

10.1007/s00401-007-0243-4

Central Brain Tumor Registry of the United States. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004–2007. Available at:http://www.cbtrus.org/2011‐NPCR‐SEER/WEB‐0407‐Report‐3–3‐2011.pdf.

10.2307/2529873

10.1016/j.ejca.2004.07.002

10.1002/sim.1597

StataCorp. 2005, 2005, Stata Statistical Software: Release 9.1 College Station

SEER. Surveillance Research Program. National Cancer Institute SEER*Stat software version 6.6.2. Available at:www.seer.cancer.gov/seerstat‐ April 13 2010.

10.1182/blood-2010-05-282632

10.3171/jns.2006.105.4.538

10.1016/j.jss.2009.04.024

10.3171/jns.1998.88.1.0001

10.1017/S0317167100034016

10.1093/jnen/64.6.479

10.1200/JCO.1997.15.9.3129

10.1212/WNL.54.7.1442

10.1007/s11864-001-0071-z

10.1002/cncr.24444

10.1002/cncr.24413

10.1517/14728220902942348

10.1159/000210017

10.1007/s11060-005-9026-8

10.1016/j.ejca.2004.02.004

10.1200/JCO.2009.23.0805

10.1227/01.NEU.0000371990.86656.E8

10.3171/jns.1998.88.5.0831

10.1158/1055-9965.EPI-08-1118

10.1093/jnci/91.16.1382

10.1016/S1470-2045(07)70246-2

10.1093/oxfordjournals.aje.a116246

10.1016/S0140-6736(04)16153-9

Agar NY, 2010, Development of stereotactic mass spectrometry for brain tumor surgery, Neurosurgery

10.1016/S1470-2045(07)70245-0

10.1038/sj.bjc.6605402

Thông tin
Thông tin xuất bản

International Journal of Cancer

Tập 131 Số 1

173-185

Thông tin tác giả